Poly-ICLC Molecular Weight Control for MDA5 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Poly-ICLC molecules lack control over the molecular weight of polyribonucleotide components, which is crucial for optimizing biological activity and clinical effectiveness, particularly in activating the MDA5 pathway for antitumor, antiviral, and anti-inflammatory effects.
Innovation Solution
The development of Poly-ICLC molecules with specific molecular weight ranges for poly-I and poly-C components, such as 0.4-5 kilobases for poly-I and 2-8 kilobases for poly-C, which enhance activation of the MDA5 and TLR3 enzyme systems, allowing for optimized biological activity and improved clinical outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If poly-ICLC is produced without controlling molecular weight of polyribonucleotide components, then production is simpler and more flexible, but biological activity and clinical effectiveness are not optimized
Solution Approach 1:
The patent applies parameter changes by establishing specific molecular weight ranges for poly-I (0.4-5 kb) and poly-C (2-8 kb) components to optimize biological activity. This controlled parameter approach resolves the contradiction by defining precise manufacturing specifications that enhance MDA5 pathway activation while maintaining feasible production through standardized ranges rather than exact values.
2Reliability
If poly-ICLC with specific molecular weight ranges is produced, then biological activity and MDA5 activation are enhanced, but production and quality control become more complex
Solution Approach 1:
The patent defines specific molecular weight ranges (poly-I: 0.4-5 kb, poly-C: 2-8 kb) that optimize MDA5 activation and biological activity. By establishing these parameter ranges, the patent achieves reliable and consistent biological effects while providing clear manufacturing specifications, thus resolving the contradiction between reliability and manufacturing precision.
3Reliability
If poly-ICLC formulation is optimized for MDA5 activation, then antitumor, antiviral, and anti-inflammatory effects are enhanced, but formulation complexity increases
Solution Approach 1:
The patent optimizes formulation by specifying molecular weight ranges for poly-I and poly-C components that enhance MDA5 pathway activation and clinical effectiveness. This parameter-based approach achieves reliable therapeutic effects while maintaining manageable formulation complexity through clearly defined component specifications rather than complex multi-parameter optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized molecular weight ranges of Poly-ICLC molecules significantly enhance antitumor, antiviral, and anti-inflammatory effects by activating the MDA5 and TLR3 pathways, providing effective prophylaxis, treatment, and inflammatory symptom attenuation for various infections and cancers.
Implementation Method 1
The polylysine component in Poly-ICLC acts as a transfection agent, bursting the endosome through a proton sponge effect and delivering the drug into the cytoplasm
Implementation Method 2
When properly administered to patients, Poly-ICLC functions essentially as a viral mimic or immune 'danger signal'; it does not carry a specific genetic message, nor does it replicate
Implementation Method 3
more recent studies have demonstrated additional unique multidimensional actions of poly-ICLC that are mediated largely through other PRRs, most notably the cytoplasmic dsRNA dependent Melanoma differentiation-associated protein 5 helicase (MDA5)
Implementation Method 4
Plain poly-IC and various derivatives are generally considered to exert their immunostimulatory actions through the pattern recognition receptor (PRR) toll-like receptor 3 (TLR3), with induction of IFNb and activation of dendritic cells
Data Source
AI summary
Poly-ICLC molecules and methods for producing them, including certain specific molecular weight molecules having improved activity in certain applications. These molecules may be incorporated in pharmaceutically or veterinary acceptable excipients and carriers for a number of uses in humans, in domestic animals and in wild animals. Such uses include (but are not limited to) prophylaxis pre-exposure prophylaxis, treatment and/or inflammatory symptom attenuation of viral or microbial infections; immunomodulating, vaccine adjuvant, antiviral, and/or anti-inflammatory effects mediated through activation of the MDA5, TLR3 and other dsRNA dependent enzyme systems; antineoplastic effects either alone or when combined with therapeutic vaccine or other anticancer immunologic agents; preventive cancer vaccine adjuvant effects in patients at risk for cancer. The molecules may be of particular use against SARS-CoV-2 infection or a cytokine storm caused by a SARS-CoV-2 infection. While dosage may be adjusted depending on the specific target and the specific patient, the dose should be sufficient to activate the MDA5 and TLR3 enzyme systems in the patient. For humans the dose is between approximately 0.5 and 50 micrograms per kilogram body weight. The nature of the molecule does not demand any specific route of administration. Therefore, the route can be selected based on the specific target and the specific patient, and could include (but not be limited to) IM, SC, IT, IV or IN. Preferably, administration would comprise two or three repeated dose cycles spaced 24 to 96 hours apart. Depending on the target and the patient's response, dose cycles may be repeated 2 to 4 times per month.